• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Adaptive Biotechnologies Corporation

    2/27/26 5:05:19 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADPT alert in real time by email
    S-8 1 d105844ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 27, 2026

    Registration No. 333- 

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ADAPTIVE BIOTECHNOLOGIES CORPORATION

    (Exact name of Registrant as specified in its charter)

     

     

     

    Washington   27-0907024

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    1165 Eastlake Avenue East

    Seattle, Washington

      98109
    (Address of Principal Executive Offices)   (Zip Code)

    Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan

    (Full Title of the Plans)

    Chad Robins

    Chief Executive Officer

    Adaptive Biotechnologies Corporation

    1165 Eastlake Avenue East

    Seattle, Washington 98109

    (206) 659-0067

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Andrew Ledbetter

    DLA Piper LLP (US)

    701 Fifth Avenue, Suite 6900

    Seattle, Washington 98104

    Telephone: (206) 839-4800

    Facsimile: (206) 839-4801

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 14,943,083 shares of the common stock of Adaptive Biotechnologies Corporation (the “Company”), par value $0.0001 per share (“Common Stock”), issuable under the 2019 Equity Incentive Plan (the “2019 EIP”) for which registration statements of the Company on Form S-8 filed with the Commission on July 1, 2019 (File No.  333-232495) and February 14, 2023 (File No.  333-269767) (the “Prior Registration Statements”) are effective, as a result of the operation of automatic annual increases provided for therein on January 1, 2024 and January 1, 2026, added 14,943,083 shares of Common Stock. In accordance with Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made a part of this Registration Statement on Form S-8.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Not filed as part of this Registration Statement pursuant to the instructions to Part I of Form S-8.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT


    Item 3. Incorporation of Documents by Reference.

    The following documents filed with the Commission by the Company pursuant to the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are hereby incorporated by reference in this registration statement:

     

      (a)

    The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Commission on February 26, 2026; and

     

      (b)

    The Company’s registration statement on Form 8-A (File No. 001-38957) filed with the Commission on June 26, 2019 pursuant to Section 12(b) of the Exchange Act, relating to the Company’s Common Stock, including all other amendments and reports filed for the purpose of updating such description.

    All documents that the registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this registration statement (except for any portions of the registrant’s current reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission) and prior to the filing of a post-effective amendment to this registration statement indicating that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of filing of such documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    RCW 23B.08.320 permits a Washington corporation to, through its articles of corporation, eliminate or limit the personal liability of a director to the corporation or its shareholders for monetary damages for conduct as a director, except for the following:

     

      •  

    acts or omissions that involve intentional misconduct by a director or a knowing violation of law by a director;

     

      •  

    conduct violating RCW 23B.08.310 relating to unlawful distributions;

     

      •  

    any transaction from which the director will personally receive a benefit in money, property or services to which the director is not legally entitled; and

     

      •  

    any act or omission occurring prior to the date when the provision in the articles of incorporation eliminating or limiting liability becomes effective.

    RCW 23B.08.510 authorizes a Washington corporation to indemnify an individual made a party to a proceeding because the individual is or was a director against liability incurred in the proceeding if:

     

      •  

    the individual acted in good faith;


      •  

    the individual reasonably believed (a) in the case of conduct in the individual’s official capacity with the corporation, that the individual’s conduct was in its best interests and (b) in all other cases, that the individual’s conduct was at least not opposed to its best interests; and

     

      •  

    in the case of any criminal proceeding, the individual had no reasonable cause to believe the individual’s conduct was unlawful.

    Notwithstanding the foregoing, a Washington corporation may not indemnify a director under RCW 23B.08.510 in connection with (a) a proceeding by or on behalf of the corporation in which the director was adjudged liable to the corporation or (b) any other proceeding charging improper personal benefit to the director, in which the director was adjudged liable on the basis that personal benefit was improperly received by the director. Additionally, where a proceeding is by or on behalf of the corporation, the indemnification permitted under RCW 23B.08.510 is limited to reasonable expenses incurred in connection with the proceeding.

    RCW 23B.08.520 mandates a Washington corporation to indemnify a director who was wholly successful, on the merits or otherwise, in the defense of any proceeding to which the director was a party because of being a director of the corporation against reasonable expenses incurred by the director in connection with the proceeding, unless such indemnification is limited in the corporation’s articles of incorporation. Our amended and restated articles of incorporation do not contain any such limitation.

    RCW 23B.08.540 permits court-ordered indemnification, unless a corporation’s articles of incorporation provide otherwise. Pursuant to this provision, in the absence of a contrary provision in a corporation’s articles of incorporation, a director who is a party to a proceeding may apply for indemnification or advance of expenses to the court conducting the proceeding or to another court of competent jurisdiction, and such court may order indemnification or advance of expenses if it makes certain determinations.

    Under RCW 23B.08.570, unless a corporation’s articles of incorporation provide otherwise, an officer of a Washington corporation who is not a director is also entitled to mandatory indemnification under RCW 23B.08.520 and court-ordered indemnification under RCW 23B.08.540, each of which sections are summarized above, to the same extent as a director. Further, a Washington corporation may indemnify an officer, employee or agent of the corporation under RCW 23B.08.510, to the same extent as a director.

    RCW 23B.08.580 permits a corporation to purchase and maintain insurance on behalf of any individual who is or was a director, officer, employee or agent of the corporation, or who while a director, officer, employee or agent of the corporation, is or was serving at the corporation’s request as a director, officer, partner, trustee, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, against liability asserted against or incurred by the individual in that capacity or arising from the individual’s status as a director, officer, employee or agent, whether or not the corporation would have power to indemnify such individual against the same liability under RCW 23B.08.510 and 23B.08.520.

    Our amended and restated articles of incorporation and our amended and restated bylaws provide that we will indemnify our directors and officers to the fullest extent permitted under Washington law.

    We have entered into indemnification agreements with certain of our current directors and executive officers, and may enter into indemnification agreements with future directors and executive officers, to provide such directors and officers, additional contractual assurances regarding the scope of the indemnification set forth in our amended and restated articles of incorporation and our amended and restated bylaws and to provide additional procedural protections.

    We may also purchase and maintain liability insurance on behalf of our directors, officers, employees and agents. We currently maintain a liability insurance policy pursuant to which our directors and officers may be indemnified against liability incurred as a result of serving in their capacities as directors and officers, subject to certain exclusions, including liabilities under the Securities Act.


    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    The following Exhibits are being filed as part of this Registration Statement:

     

    Exhibit
    Number

      

    Exhibit Title

      

    Filed/Furnished
    Herewith

      

    Form

      

    File No.

      

    Exhibit

      

    Filing
    Date

    4.1    Amended and Restated Articles of Incorporation       8-K    001-38957    3.1    7/1/2019
    4.2    Amended and Restated Bylaws       8-K    001-38957    3.2    7/1/2019
    5.1    Opinion of DLA Piper LLP (US)    X            
    23.1    Consent of DLA Piper LLP (US) (included in Exhibit 5.1)    X            
    23.2    Consent of Independent Registered Public Accounting Firm    X            
    99.1#    Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and form of award agreement thereunder       10-Q    001-38957    10.12    8/13/2019
    99.2#    Form of Stock Option Agreement for Non-U.S. Participants       10-K    001-38957    10.16    2/24/2021
    99.3#    Form of Restricted Stock Unit Agreement for Non-U.S. Participants       10-K    001-38957    10.17    2/24/2021
    99.4#    Form of Performance Units Agreement and Notice of Grant of Performance Units       10-Q    001-38957    10.1    5/4/2022
    107    Filing Fees Table    X            
     
    #

    Indicates management contract or compensatory plan.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington, on this 27th day of February, 2026.

     

    Adaptive Biotechnologies Corporation
    By:  

    /s/ Chad Robins

      Chad Robins
      Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Chad Robins and Kyle Piskel and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature

      

    Title

      

    Date

    /s/ Chad Robins

    Chad Robins

      

    Chief Executive Officer and Director

    (Principal Executive Officer)

       February 27, 2026

    /s/ Kyle Piskel

    Kyle Piskel

      

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

       February 27, 2026

    /s/ Michelle Griffin

    Michelle Griffin

       Director    February 27, 2026

    /s/ Robert Hershberg

    Robert Hershberg, PhD, MD

       Director    February 27, 2026

    /s/ Peter Neupert

    Peter Neupert

       Director    February 27, 2026

    /s/ Katey Owen

    Katey Owen, PhD

       Director    February 27, 2026
    Get the next $ADPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADPT

    DatePrice TargetRatingAnalyst
    12/2/2025$21.00Equal-Weight
    Morgan Stanley
    9/30/2025$20.00Buy
    Guggenheim
    6/18/2025$15.00Buy
    Craig Hallum
    3/21/2025$9.00Neutral → Buy
    Goldman
    7/5/2023$15.00Overweight
    JP Morgan
    1/5/2023$15.00Sector Outperform
    Scotiabank
    12/21/2022$7.50 → $14.00Neutral → Overweight
    Piper Sandler
    8/25/2022$8.00Underperform
    Credit Suisse
    More analyst ratings

    $ADPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

    SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 was an outstanding year for Adaptive, marked by strong execution and meaningful progress across the business," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "We delivered 46% revenue growth and achieved profitability in our MRD business, while advancing our Immune Medici

    2/5/26 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

    SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UTParticipating on Tuesday, February 10, 2026TD Cowen 46th Annual Health Care Conference in Boston, MAFireside chat on Monday, March 2, 2026, at 11:50 a.m. Eastern Time Interested parties may access live and archived webcasts of the session on the "Investors" se

    1/27/26 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

    SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for repl

    1/22/26 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Piskel Kyle exercised 2,145 shares at a strike of $12.14 and sold $39,597 worth of shares (2,145 units at $18.46) (SEC Form 4)

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    2/6/26 7:30:18 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Robins Harlan S sold $799,105 worth of shares (42,788 units at $18.68), decreasing direct ownership by 4% to 1,179,524 units (SEC Form 4)

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    2/4/26 7:48:48 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO and Chairman Robins Chad M sold $2,304,963 worth of shares (124,998 units at $18.44), decreasing direct ownership by 5% to 2,459,245 units (SEC Form 4)

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    2/4/26 7:37:09 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Adaptive Biotechnologies with a new price target

    Morgan Stanley resumed coverage of Adaptive Biotechnologies with a rating of Equal-Weight and set a new price target of $21.00

    12/2/25 8:23:20 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Adaptive Biotechnologies with a new price target

    Guggenheim initiated coverage of Adaptive Biotechnologies with a rating of Buy and set a new price target of $20.00

    9/30/25 8:35:50 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum initiated coverage on Adaptive Biotechnologies with a new price target

    Craig Hallum initiated coverage of Adaptive Biotechnologies with a rating of Buy and set a new price target of $15.00

    6/18/25 8:08:30 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    SEC Filings

    View All

    SEC Form S-8 filed by Adaptive Biotechnologies Corporation

    S-8 - Adaptive Biotechnologies Corp (0001478320) (Filer)

    2/27/26 5:05:19 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Adaptive Biotechnologies Corporation

    10-K - Adaptive Biotechnologies Corp (0001478320) (Filer)

    2/26/26 4:31:07 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)

    2/5/26 4:15:24 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

    For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

    3/5/21 10:37:33 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    Financials

    Live finance-specific insights

    View All

    Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

    SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 was an outstanding year for Adaptive, marked by strong execution and meaningful progress across the business," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "We delivered 46% revenue growth and achieved profitability in our MRD business, while advancing our Immune Medici

    2/5/26 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

    SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for repl

    1/22/26 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

    SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2025. "Our third quarter results reflect another period of strong growth and financial progress," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "Our MRD business has reached a major inflection point, having achieved both profitability and cash flow positivity, driven by disciplined execution and acce

    11/5/25 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    Leadership Updates

    Live Leadership Updates

    View All

    Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors

    Cohen to serve as Chair of the Audit Committee Grindr Inc. (NYSE:GRND), the Global Gayborhood in Your Pocket™, today announced the appointment of Chad Cohen, former Chief Financial Officer of Zillow Group Inc. (NASDAQ:Z) and Adaptive Biotechnologies Corp. (NASDAQ:ADPT) and Founding Partner of Scala Advisors, LLC, to Grindr's Board of Directors as of June 3, 2025. Cohen was also appointed to serve as the Chair of Grindr's Audit Committee. A seasoned public company finance executive and board member, Cohen has helped grow several multi-billion dollar technology companies, including multiple leading consumer Internet brands. Prior to his current role, Cohen served as the Chief Financial Of

    6/3/25 4:05:00 PM ET
    $ADPT
    $GRND
    $TRUP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Computer Software: Programming Data Processing
    Technology

    Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

    SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Tycho Peterson as chief financial officer (CFO). Mr. Peterson brings several decades of financial leadership and experience within the life science and diagnostic industries. "Tycho has been a leader in this space over the last two decades, during which disruptive technologies such as genomic sequencing and artificial intelligence have driven a complete paradigm shift in diagnostics and precision medic

    3/9/22 7:00:00 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

    SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately. Nitin brings more than 15 years of proven commercial experience at leading life sciences and diagnostics companies, most recently at Guardant Health. "Adaptive has set the stage for commercial success with well-defined growth strategies and a solid pipeline for our current research and diagnostic products. Nit

    8/4/21 4:15:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Adaptive Biotechnologies Corporation

    SC 13G - Adaptive Biotechnologies Corp (0001478320) (Subject)

    11/13/24 4:30:24 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

    SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

    11/13/24 9:00:21 AM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adaptive Biotechnologies Corporation

    SC 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)

    11/12/24 1:30:57 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care